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ABSTRACT
Dialysis patients have high mortality rate and the leading
cause of death is cardiovascular disease. Uremic cardio-
myopathy differs from that due to conventional athero-
sclerosis, where cardiovascular changes result in
ineffective circulation and lead to tissue ischemia. Modern
dialysis has significant limitations with fluid management
probably the most challenging. Current evidence suggests
that both volume overload and aggressive fluid removal
can induce circulatory stress and multi-organ injury. Fur-
thermore, we do not have accurate volume assessment
tools. As a result, targeting euvolemia might result in
more harm than benefit with conventional hemodialysis
therapy. Therefore, it might be time to consider a degree
of permissive over-hydration until we have better tools to
both determine ideal weight and improve current renal
replacement therapy so that the process of achieving it is
not so fraught with the current dangers.
Despite continuous advancements in dialysis ther-
apies, the mortality rate of dialysis patients remains
high at 60% after 5 years of dialysis treatment
(1,2). The leading causes of death in dialysis
patients are cardiovascular in origin. The patho-
physiology of these cardiovascular comorbidities
differs from those associate with conventional ath-
erosclerosis. These differences are structural (vascu-
lar calcification is medial rather than intimal),
biochemical (calcium-phosphate products are
increased) and functional (congestive heart failure
and contractile dysfunction are common). As a
result, treating traditional cardiovascular risk
factors has not significantly improved survival in
patients with chronic kidney disease (CKD) (3–6).
The development of uremic cardiomyopathy is
likely multifactorial. The uremia itself may cause
inflammation, congestive heart failure and volume
overload, which lead to cardiovascular remodeling
and calcification (7,8). For example, one of the
products that accumulate in the state of uremia is
fibroblast growth factor 23 (FGF23), a protein that
is be markedly elevated in CKD stage 5. It is
strongly associated with CKD patient survival, and
may contribute to myocardial fibrosis (9). As a
result, cardiovascular remodeling and calcification
results in stiffening and ineffective macro- and
micro-vascular circulation. These changes have
primed patients for demand ischemia, and have
impaired the ability for patients to tolerate fluid
removal, which result in long-term volume overload.
Furthermore, the volume overload commonly seen
in CKD alone can also increase TNF-a, leading to
inflammation, fibrosis, and cardiac dilation (10). By
contrast, too much fluid removal can result in intra-
dialytic injury leading to a reduction in residual
renal function, which aggravates fluid accumulation.
The aim of this review is to critically evaluate the
common clinical goal of targeting euvolemia in dial-
ysis patients.
Volume Overload and Cardiovascular
Outcomes
Volume overload is common in dialysis patients.
It is associated with increased cardiovascular
morbidity and mortality (11). Extracellular fluid
expansion is associated with left ventricular hyper-
trophy (LVH) and cardiac fibrosis (12,13). Volume
overload is also strongly associated with LVH and
improving volume control can lead to left ventricu-
lar mass regression (14). For example, salt
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restriction resulted in a reduction in inter-dialytic
weight gain and left ventricular mass without a
change in pre-dialysis blood pressure (15). LVH
and left ventricular dilation are associated with an
increased rate of sudden cardiac death and
other cardiovascular morbidity and mortality
(16,17). In contrast, a decrease in left ventricular
mass over time is associated with lower rates of
death and cardiovascular events (16,18). It is
therefore reasonable to assume that our aim
should be to tightly control fluid status and to
aggressively remove fluid in order to avoid volume
overload in dialysis patients. Still, achieving a
“true dry weight” in dialysis patients can be chal-
lenging and even impossible, and there may be a
price to pay.
The Challenge of Targeting Euvolemia
The Challenge of Achieving a Dry Weight in
All Patients
Dry weight is currently defined as “the lowest tol-
erated post-dialysis weight achieved with minimal
signs or symptoms of hypo- or hypervolemia” (19).
This definition is, however, incomplete. Some
patients may meet the above definition but are in
chronic volume overload because of intra-dialytic
hypotension and/or symptoms related to dialysis
and ultrafiltration. Intra-dialytic hypotension is
common in dialysis patients (15–30% of all dialysis
treatments) and has proven to pose a clinical chal-
lenge (20). Intra-dialytic hypotension can result
from hypovolemia, from an inadequate hemody-
namic response from the sympathetic nervous
system and a slow refilling rate, from autonomic
dysfunction, or from underlying cardiac disease.
Despite employing strategies to avoid intra-dialytic
hypotension, patients may still experience these
symptoms and may be unable to reach their set
target weight.
What is the Ideal Weight?
There is currently no gold standard measure-
ment for dry weight. Heavy water total body
water measurement has been used to measure
total body water, but it is costly and is not avail-
able in all centers (21). Other methods such as
clinical assessment of dry weight by evaluating
edema, blood pressure, jugular venous extension
and/or biomarkers (such as B-type natriuretic pep-
tide, the N-terminal pro-B-type natriuretic peptide
and troponin) do not always correlate with vol-
ume overload (22,23). For example, N-terminal
pro-B-type level is influenced by the degree of
renal impairment and by the underlying cardiovas-
cular disease.
Measuring relative plasma volume through rela-
tive hematocrit concentration is another way of
assessing dry weight. This method is incorporated
in some hemodialysis machines and has shown some
prognostic importance in dialysis outcomes (11).
Nevertheless, the Crit-Line Intra-dialytic Monitor-
ing Benefit Study showed increased mortality in
patients who were dialyzed with blood volume mon-
itoring (24).
Ultrasound measurement of the inferior vena
cava has also been studied as an option for
assessing dry weight, but it can only assess intra-
vascular volume (25). It is therefore neither sensi-
tive nor specific enough for volume overload and
can be influenced by underlying heart failure. This
drawback has impeded its routine use in clinical
practice.
More recent studies have examined the applica-
tion of bioimpedance spectroscopy to assess volume.
This method measures resistance and reactance to
determine total body water and to differentiate
intracellular and extracellular fluid. A multi-fre-
quency bioimpedance device such as the body com-
position monitor (BCM, Fresenius Medical Care,
Bad Homburg, Germany) has shown some promis-
ing results (26–29). Still, this device has only been
tested on a limited scale and cannot be used in cer-
tain patients. More research is required to deter-
mine which method is optimal for determining dry
weight.
The Negative Consequences of Large
Volume Removal
Studies have shown that residual renal function is
an important prognostic marker for dialysis patients
(30,31). This is likely related to both fluid removal
and uremic toxin clearance. Preserving residual
renal function is an important goal. Researchers
have identified several factors that can predict a
decline in residual renal function. Of these, perito-
neal dialysis is more adept at preserving residual
renal function than hemodialysis, and intra-dialytic
hypotension and episodes of dehydration are associ-
ated with a more rapid decline in residual renal
function (32).
Myocardial stunning, left ventricular dysfunction
from transient myocardial ischemia which persists
after reperfusion, has been well described in the
cardiology literature. Since patients with end-stage
renal disease are prone to cardiac ischemia, the
hemodynamic stress of hemodialysis may produce
such stunning. Burton et al. showed that the
myocardium of 67% of patients stunned during
hemodialysis treatments (33). Repetitive stunning
can lead to myocardial remodeling and fibrosis
and a fixed reduction in cardiac function (34).
Patients who have experienced 1 year of hemodial-
ysis-associated myocardial stunning have a higher
mortality rate than those hemodialysis patients
who do not exhibit such stunning (35). It is not
surprising that cardiac stunning during hemodialy-
sis is associated with a reduction in intravascular
volume and systolic blood pressure, which reduces
myocardial perfusion, bringing about cardiac
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ischemia (35,36). This reduction in blood perfu-
sion can also take place in other organs, including
the brain and gut (37).
Clinical Dilemma
With the above information in mind, the practic-
ing nephrologist is presented with a clinical
dilemma. A variety of constraints have led to short-
ened hemodialysis treatments at the same time as
the dialysis population has become more at risk of
hemodynamic instability during treatment; this has
rendered chronic volume overload a considerable
clinical challenge. Volume overload is associated
with long-term cardiovascular complications in dial-
ysis patients including a poor survival rate. In con-
trast, removing excessive fluid in an attempt to
achieve a euvolemic state can also lead to poor
patient outcomes in conventional thrice-weekly he-
modialysis by evoking intra-dialytic hypotension,
myocardial stunning and loss of residual renal func-
tion. It is likely that many patients would benefit
from some volume reserve to avoid myocardial
stunning and other organ ischemia.
Volume control in dialysis patients may, in fact,
be somewhat analogous to blood glucose control in
diabetic patients. Studies have shown that adequate
blood glucose control reduces microvascular and/or
macrovascular complications in diabetic patients
(38). Yet targeting normal hemoglobin A1C by way
of intense therapy can lead to a higher risk of hypo-
glycemic events and death (39). Similarly, we must
avoid chronic excessive volume overload as well as
symptomatic episodes of intravascular depletion in
patients being treated with conventional 4-hour
thrice-weekly hemodialysis. We may need to
increase the target weights of at risk patients,
acknowledging that they are above ideal values, to
avoid hypotension and all its associated ill effects.
The amount of this “permissive fluid” must be indi-
vidualized, depending on the patient’s underlying
cardiovascular status and treatment tolerance.
Fluid Management in Dialysis Patients
Such a permissive increase in target weight should
not be undertaken until every effort has been made
to improve intradialytic hemodynamics. The value
of increased treatment time is obvious as is the criti-
cal role of sodium balance for volume control. The
value of reducing salt intake cannot be overempha-
sized; however, it requires patient adherence to a
difficult diet. The commonplace dialysate sodium of
140 mmol/l is not optimal for all patients. When
dialysate sodium concentration is higher than the
pre-dialysis plasma sodium a positive diffusive
sodium balance will occur requiring increased con-
vective loss by ultrafiltration; inter-dialytic weight
gain and volume overload will be exacerbated (40).
A patient’s dialysate sodium concentration should
be individualized based on pre-dialysis plasma
sodium levels in order to avoid this positive diffu-
sive sodium balance and volume overload. The abil-
ity to decrease sodium absorption from the
gastrointestinal tract, using medications such as ten-
apanor (an inhibitor of the sodium-proton exchan-
ger in the gastrointestinal tract and kidney) is an
exciting development and may have some role in
the future (41).
Another simple and effective intervention is to
lower the temperature of the dialysate which
reduces vascular dilatation and limits intra-dialytic
hypotension and myocardial stunning. McIntyre
et al. looked at the benefits of cooling the dialysate
to 0.5°C below core temperature in 73 randomized
patients; both groups (cooled and standard dialy-
sate) were matched in their ultrafiltration volume
(42). Dialysate cooling preserved left ventricular
function, reduced myocardial stunning and lowered
the risk of vascular injury to the brain.
Although peritoneal dialysis is a continuous ther-
apy, it is also associated with a high rate of chronic
volume overload and high cardiovascular morbidity
which may, in part, be related to a large glucose
load and chronic inflammation (43,44). In contrast,
hemodialysis patients who suffer from chronic vol-
ume overload may benefit from frequent and/or
nocturnal hemodialysis which can reverse left ven-
tricular hypertrophy, reduce left and right ventricu-
lar volume, and improve patient survival (45). The
Frequent Hemodialysis Network Trials, the two
largest randomized controlled studies comparing
short-hour daily hemodialysis and nocturnal
hemodialysis to thrice-weekly hemodialysis (46,47),
showed that increased hemodialysis frequency with
or without an increase in duration may improve
cardiovascular outcomes in dialysis patients.
A change in frequency and/or duration may
improve volume and hemodynamic control during
and after the treatment.
Conclusion
Since the 1960s, dialysis has progressed from an
experimental treatment to a mature therapy.
Although effective for sustaining life, modern dialy-
sis has significant limitations. Fluid management is
challenging as a result of the non-physiologic nature
of hemodialysis with its limited duration and fre-
quency. Current evidence suggests that both volume
overload and aggressive fluid removal can induce
circulatory stress and multi-organ injury. Perhaps,
targeting the “Holy Grail” of euvolemia results in
more cardiovascular injury in this population than
previously realized and is a factor in the poor
patient outcomes with conventional hemodialysis
therapy. At the current time, we do not have “con-
tinuous” hemodialysis therapy to avoid the demand
ischemia of reaching the ideal fluid control. Is it
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time to consider some permissive over-hydration, to
a level that prevents “removal stress” but is short of
damaging overload? Future investigator-initiated
research plus technical and clinical innovations are
needed to develop better tools to assess volume
status so that our goals are clear and to improve
current renal replacement therapy so that achieving
them are less problematic.
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